H
Hisato Kawakami
Researcher at Kindai University
Publications - 165
Citations - 3646
Hisato Kawakami is an academic researcher from Kindai University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 107 publications receiving 1913 citations. Previous affiliations of Hisato Kawakami include Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara,Yung-Jue Bang,Satoru Iwasa,Naotoshi Sugimoto,Min-Hee Ryu,Daisuke Sakai,Hyun-Cheol Chung,Hisato Kawakami,Hiroshi Yabusaki,Jeeyun Lee,Kaku Saito,Yoshinori Kawaguchi,Takahiro Kamio,Akihito Kojima,Masahiro Sugihara,Kensei Yamaguchi,DESTINY-Gastric Investigators +16 more
TL;DR: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based lin...
Journal ArticleDOI
Microsatellite instability testing and its role in the management of colorectal cancer.
TL;DR: To increase the identification of dMMR/MSI patients in clinical practice that includes those with Lynch syndrome, it is recommended that all resected CRCs to be analyzed for MMR status.
Journal ArticleDOI
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.
K. Muro,E. Van Cutsem,Yukiya Narita,Georgios Pentheroudakis,Eishi Baba,Jian Li,Min-Hee Ryu,W.I. Wan Zamaniah,W.P. Yong,K.-H. Yeh,Kyoko Kato,Zhihao Lu,Byoung Chul Cho,I.M. Nor,M. Ng,L.-T. Chen,Takako Eguchi Nakajima,Kohei Shitara,Hisato Kawakami,Takahiro Tsushima,Takayuki Yoshino,Florian Lordick,Erika Martinelli,Elizabeth C Smyth,Dirk Arnold,Hironobu Minami,Josep Tabernero,J.-Y. Douillard +27 more
TL;DR: These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS).
Journal ArticleDOI
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Yuichiro Doki,Jaffer A. Ajani,Ken Kato,Jianming Xu,Lucjan Wyrwicz,Satoru Motoyama,Takashi Ogata,Hisato Kawakami,Chih-Hung Hsu,Antoine Adenis,Farid El Hajbi,Maria Di Bartolomeo,Maria Ignez Braghiroli,Eva Holtved,Sandra Anabel Ostoich,Hye-Ri Kim,Masaki Ueno,Wasat Mansoor,Wen-Chi Yang,Tianshu Liu,John Bridgewater,Tomoki Makino,Ioannis D. Xynos,Xuan Liu,Ming Lei,Kaori Kondo,Apurva Patel,Joseph Gricar,Ian Chau,Yuko Kitagawa +29 more
TL;DR: Overall survival was significantly longer with nivolumab plus chemotherapy than with chemotherapy alone, both among patients with tumor-cell PD-L1 expression of 1% or greater and in the overall population.
Journal ArticleDOI
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Salvatore Siena,Maria Di Bartolomeo,Kanwal Pratap Singh Raghav,Toshiki Masuishi,Fotios Loupakis,Hisato Kawakami,Kensei Yamaguchi,Tomohiro Nishina,Marwan Fakih,Elena Elez,Javier Rodríguez,Fortunato Ciardiello,Yoshito Komatsu,Taito Esaki,Ki Y Chung,Zev A. Wainberg,Andrea Sartore-Bianchi,Kapil Saxena,Eriko Yamamoto,Emarjola Bako,Yasuyuki Okuda,Javad Shahidi,Axel Grothey,Takayuki Yoshino,Destiny-Crc investigators +24 more
TL;DR: The DESTINY-CRC01 trial as discussed by the authors showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with that reported in previous trastuzumab deruxtecan trials.